Name | Number of supported studies | Average coverage | |
---|---|---|---|
transit amplifying cell | 3 studies | 29% ± 7% |
Insufficient scRNA-seq data for expression of BUB1B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 97% | 1178.23 | 1753 / 1809 | 93% | 15.62 | 440 / 472 |
lung | 76% | 200.99 | 437 / 578 | 88% | 15.17 | 1021 / 1155 |
intestine | 55% | 297.59 | 530 / 966 | 96% | 17.59 | 508 / 527 |
stomach | 48% | 178.62 | 172 / 359 | 98% | 17.57 | 279 / 286 |
esophagus | 44% | 339.51 | 643 / 1445 | 100% | 25.23 | 183 / 183 |
breast | 43% | 68.92 | 198 / 459 | 91% | 13.82 | 1022 / 1118 |
bladder | 24% | 34.33 | 5 / 21 | 92% | 14.99 | 463 / 504 |
ovary | 16% | 38.33 | 29 / 180 | 97% | 13.48 | 417 / 430 |
uterus | 15% | 27.24 | 25 / 170 | 97% | 21.53 | 446 / 459 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.50 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 98% | 24.46 | 44 / 45 |
spleen | 98% | 582.62 | 235 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 22.14 | 27 / 29 |
pancreas | 13% | 16.62 | 41 / 328 | 73% | 5.67 | 130 / 178 |
adrenal gland | 53% | 87.33 | 136 / 258 | 17% | 1.29 | 39 / 230 |
prostate | 37% | 49.53 | 91 / 245 | 26% | 1.48 | 130 / 502 |
brain | 10% | 10.36 | 265 / 2642 | 48% | 5.71 | 340 / 705 |
thymus | 32% | 44.08 | 208 / 653 | 26% | 3.96 | 157 / 605 |
liver | 16% | 41.31 | 36 / 226 | 40% | 3.15 | 164 / 406 |
peripheral blood | 50% | 1592.10 | 462 / 929 | 0% | 0 | 0 / 0 |
kidney | 27% | 56.03 | 24 / 89 | 18% | 1.16 | 164 / 901 |
adipose | 34% | 62.03 | 405 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 20% | 0.88 | 16 / 80 |
blood vessel | 15% | 21.05 | 199 / 1335 | 0% | 0 | 0 / 0 |
heart | 14% | 20.59 | 122 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 1.55 | 13 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071459 | Biological process | protein localization to chromosome, centromeric region |
GO_0007091 | Biological process | metaphase/anaphase transition of mitotic cell cycle |
GO_0051301 | Biological process | cell division |
GO_0051754 | Biological process | meiotic sister chromatid cohesion, centromeric |
GO_0006915 | Biological process | apoptotic process |
GO_0007094 | Biological process | mitotic spindle assembly checkpoint signaling |
GO_0005680 | Cellular component | anaphase-promoting complex |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005813 | Cellular component | centrosome |
GO_0000776 | Cellular component | kinetochore |
GO_0033597 | Cellular component | mitotic checkpoint complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000940 | Cellular component | outer kinetochore |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0004672 | Molecular function | protein kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | BUB1B |
Protein name | BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (EC 2.7.11.1) (MAD3/BUB1-related protein kinase) (hBUBR1) (Mitotic checkpoint kinase MAD3L) (Protein SSK1) |
Synonyms | MAD3L BUBR1 SSK1 |
Description | FUNCTION: Essential component of the mitotic checkpoint. Required for normal mitosis progression. The mitotic checkpoint delays anaphase until all chromosomes are properly attached to the mitotic spindle. One of its checkpoint functions is to inhibit the activity of the anaphase-promoting complex/cyclosome (APC/C) by blocking the binding of CDC20 to APC/C, independently of its kinase activity. The other is to monitor kinetochore activities that depend on the kinetochore motor CENPE. Required for kinetochore localization of CENPE. Negatively regulates PLK1 activity in interphase cells and suppresses centrosome amplification. Also implicated in triggering apoptosis in polyploid cells that exit aberrantly from mitotic arrest. May play a role for tumor suppression. . |
Accessions | D6PW95 H0YN44 ENST00000558715.5 ENST00000412359.7 [O60566-3] O60566 ENST00000287598.11 [O60566-1] ENST00000559733.5 H0YMK5 |